KẾT QUẢ ĐIỀU TRỊ BỔ TRỢ UNG THƯ ĐẠI TRÀNG GIAI ĐOẠN II, III BẰNG PHÁC ĐỒ MFOLFOX6 TẠI BỆNH VIỆN ĐA KHOA TỈNH NINH BÌNH

Abstract

Objective: To describe the clinical and subclinical characteristics of stage III and high-risk stage II colon cancer at Ninh Binh General Hospital from January 2017 to December 2023 and to evaluate the treatment outcomes of the study patient using the adjuvant mFOLFOX6 regimen. Patients and Methods: A retrospective study on 78 patients with stage III and high-risk stage II colorectal cancer who received adjuvant chemotherapy with mFOLFOX6 at Ninh Binh General Hospital from January 2017 to December 2023. Results: The male-to-female ratio was 1.52, with 70.5% of patients over 50 years old. Common symptoms included abdominal pain (79.5%) and bowel disorders (55.1%). Most patients had an ECOG PS of 0 (75%). Adenocarcinoma accounted for 88.5%. Left-sided colon cancer accounted for 54.4%. Stage II was the majority (67.9%). Most patients completed 6 cycles of treatment (93.6%), with adjuvant therapy starting 4-6 weeks post-surgery (96.1%). The 5-year disease-free survival rate was 85.5%. The 5-year overall survival rate was 87.8%. Common gastrointestinal toxicities were nausea and vomiting, mostly grade 1-2 (66.7%). Peripheral neuropathy occurred in 28.2% of patients. Hematological toxicity was rare, with a granulocyte reduction rate of 25.6% (grade 1-2 was 17.9%, grade 3 was 7.7%). Conclusion: The adjuvant mFOLFOX6 regimen improves survival and is well-tolerated in patients with stage III and high-risk stage II colon cancer.